Antibodies Against TL1A, a TNF-Family Cytokine, for the Treatment and Diagnosis of Autoimmune Inflammatory Diseases

Autoimmune inflammatory diseases occur in greater than five percent of the United States population; this disease group includes asthma, multiple sclerosis, rheumatoid arthritis, and lupus. Treatments generally include immunosuppressants or anti-inflammatory drugs, which can have serious side effects; recently, more specific immunomodulatory therapies such as TNF-alpha antagonists have been developed.

In experiments with mice, NIAMS inventors have shown that the interaction between the TNF family ligand TL1A with its receptor, DR3, is critical for development of disease in asthma, inflammatory bowel disease and multiple sclerosis. They have also developed anti-TL1A antibodies that prevent disease in mouse models of rheumatoid arthritis and inflammatory bowel disease.

This technology describes anti-mouse TL1A and anti-human TL1A monoclonal antibodies that may be useful for the development of diagnostics and therapeutics for autoimmune inflammatory disease, as well as methods of treating such disease by blocking the interaction between TL1A and DR3.

Potential Commercial Applications: Competitive Advantages:
  • Antibody-based therapeutics for autoimmune inflammatory disease
  • Diagnostics for autoimmune inflammatory disease
  • Research tools to probe the role of TL1A-DR3 interactions in the development of autoimmune disease
  • Specific immunomodulatory effect provides potential for potent therapy without inducing global immunosuppression
  • Anti-TL1A monoclonal antibodies available for further development

Development Stage:
  • Early-stage
  • In vitro data available
  • In vivo data available (animal)

Related Invention(s):


Richard Siegel (NIAMS)  ➽ more inventions...

Francoise Meylan (NIAMS)  ➽ more inventions...

Yun-Jeong Song (NIAMS)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 9,068,003 issued 2015-06-30
US Application No. 13/419,203
US Application No. 14/733,695
US Application No. 14/826,462


Meylan F, et al.

PMID 20980995

Collaboration Opportunity:

The National Institute of Arthritis and Musculoskeletal and Skin Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the anti-mouse TL1A and anti-human TL1A monoclonal antibodies. For collaboration opportunities, please contact Cecilia Pazman at

Licensing Contact:
Benfeard Williams, Ph.D.
Phone: 301-435-4507

OTT Reference No: E-073-2011-1
Updated: Sep 12, 2012